Digital pathology adoption does not usually fail because the scanner is weak or the viewer is clunky. More often, it fails because the surrounding operating model was not built to support the shift from glass slides to digital workflows.
The scanner and Image Management System (IMS) are essential, but they are not the whole answer. Real adoption happens when governance, pathologist engagement, workflow redesign, and operational ownership are designed together as one system.
Many organizations begin their digital pathology journey with a technology-first mindset. They evaluate scanners, assess image quality, compare viewer features, and focus on integration checkboxes. Those elements are important, but they are only the starting point. The real question is this: how should the organization operate as digital becomes the norm?
If that question is not answered early, even the strongest platform can underperform. A modern IMS platform can connect image acquisition, case management, collaboration, quality control, and enterprise workflows. It can create the technical foundation for scalability and AI readiness. But it cannot, by itself, fix unclear decision-making, fragmented accountability, or poorly designed processes. That is why adoption should be treated as an operating model transformation, not just a deployment.
Governance is one of the most underestimated factors in digital pathology success. Without it, decisions become inconsistent, priorities compete, and implementation slows down.
Strong governance defines who makes decisions, how exceptions are handled, what success looks like, and how progress is measured. It gives the program structure. It also creates confidence across stakeholders, because everyone understands the rules of engagement.
In an IMS-driven environment, governance is especially important because the platform touches multiple functions: pathology, IT, informatics, quality, and operations. If those groups are not aligned, the platform becomes a tool with fragmented use cases instead of a coordinated enterprise capability. Good governance does not slow innovation. It makes innovation useful and repeatable.
Pathologist engagement is another make-or-break factor. Adoption improves dramatically when pathologists are involved early, not just trained late.
In some projects, physicians are treated as end users and introduced to the system only after key decisions have already been made. Pathologists know where friction lives: case assignment, review patterns, sign-out preferences, collaboration gaps, report production and exception handling. Their input is critical to building a workflow that feels natural rather than imposed.
An IMS platform can support this kind of engagement by giving teams a shared operational view of the case lifecycle. It can help pathologists, lab leaders, and informatics teams see the same workflow, identify bottlenecks, and standardize practices. When pathologists see that the system is being designed around clinical reality, trust grows. And when trust grows, adoption follows.
One of the most common mistakes in digital pathology is digitizing a legacy workflow without redesigning it. That approach creates friction quickly. Slides are scanned, but the rest of the process remains paper-based or manually coordinated. Cases are available digitally, but assignments still rely on side channels. Quality checks happen inconsistently. Pathologists end up working across two systems, and the promise of digital becomes harder to realize. True workflow redesign means stepping back and asking how the work should flow in a digital environment:
These are not minor implementation details. They are the foundation of a sustainable digital pathology program. The best IMS platforms support this redesign by connecting people, processes, and data across the full case journey. But the organization still has to define the future state intentionally.
Even well-designed programs can lose momentum if no one owns the day-to-day operation of the digital workflow. This is where many initiatives become vulnerable. IT may own infrastructure, the lab may own slide preparation, and pathologists may own diagnostic interpretation, but no one may be accountable for the full end-to-end experience. As a result, issues linger, workarounds multiply, and adoption erodes over time.
Operational ownership closes that gap. It creates a clear accountable function for monitoring performance, resolving issues, supporting users, and driving continuous improvement. In a mature digital pathology environment, this ownership may sit within a center of excellence, a program office, or a cross-functional operations team. The exact structure matters less than the principle: someone must own the system after go-live, not just the launch.
The IMS platform is best understood as the connective tissue of the digital pathology enterprise. It is the layer that brings together acquisition, workflow management, collaboration, quality oversight, and organization visibility.
That role is powerful, but it only reaches its full potential when the organization is ready to use it as the foundation for change. The platform can support standardization, scalability, and readiness for AI, but those outcomes depend on leadership decisions outside the software itself.
This is why platform conversations should extend beyond features. They should focus on how the organization will govern the journey, engage clinicians, redesign work, and sustain ownership. When those elements are in place, the IMS becomes much more than a system. It becomes an operational advantage.
Digital pathology is entering a more mature phase. The technical barriers are lower than they were a few years ago. The opportunity now is to move from implementation to transformation. The organizations that will lead are not simply those with the newest scanners or the most advanced viewers. They will be the ones that build strong governance, involve pathologists as partners, redesign workflows with intention, and assign real operational ownership to the digital program.
That is where adoption becomes durable. That is where platform value becomes visible. And that is where digital pathology shifts from a technology project to a clinical and operational capability that can scale. The future of digital pathology will not be defined by hardware alone. It will be defined by how well organizations align people, process, and platform around a shared goal: making digital the way pathology works, not just the way it stores images.
Tribun Health helps pathology laboratories navigate every stage of digital transformation, from strategy and workflow design to enterprise deployment and long-term operational adoption. Our team works closely with healthcare organizations to build scalable, sustainable digital pathology environments aligned with clinical, operational, and enterprise goals. If your laboratory is exploring digital pathology, contact us to start the conversation